(Q37896627)

25 August 2017

1 reference

title

Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option? (English)

1 reference

25 August 2017

0 references

Marco Innamorati

3

0 references

Maurizio Pompili

object named as

Maurizio Pompili

series ordinal

1

0 references

David Lester

series ordinal

9

object named as

David Lester

1 reference

25 August 2017

10

Paolo Girardi

1 reference

25 August 2017

2

Gianluca Serafini

1 reference

25 August 2017

6

Paola Venturini

1 reference

25 August 2017

Carla Ludovica Telesforo

series ordinal

5

object named as

Ludovica Telesforo

1 reference

25 August 2017

4

Elisa Ambrosi

1 reference

25 August 2017

8

Michele Battuello

1 reference

25 August 2017

Gloria Giordano

7

1 reference

25 August 2017

publication date

1 July 2011

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

25 August 2017

number of pages

18

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

7

1 reference

25 August 2017

page(s)

989-1006

1 reference

Assessment and treatment of suicide risk in schizophrenia

25 August 2017

cites work

1 reference

Stimulating the development of drug treatments to improve cognition in schizophrenia

21 January 2018

1 reference

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

21 January 2018

1 reference

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

21 January 2018

1 reference

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

21 January 2018

1 reference

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

21 January 2018

1 reference

Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care

21 January 2018

1 reference

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline

21 January 2018

1 reference

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

21 January 2018

1 reference

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

21 January 2018

1 reference

Efficacy of newer generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

Causes of the excess mortality of schizophrenia

21 January 2018

1 reference

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

Ziprasidone in the management of schizophrenia : the QT interval issue in context

21 January 2018

1 reference

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

21 January 2018

1 reference

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

21 January 2018

1 reference

Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).

21 January 2018

1 reference

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

Compliance with medication regimens for mental and physical disorders

21 January 2018

1 reference

Determinants of medication compliance in schizophrenia: empirical and clinical findings

21 January 2018

1 reference

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program

21 January 2018

1 reference

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia

21 January 2018

1 reference

A Systematic Review of Mortality in Schizophrenia

21 January 2018

1 reference

Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?

21 January 2018

1 reference

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?

21 January 2018

1 reference

Metabolic risk during antipsychotic treatment

21 January 2018

1 reference

Mortality and causes of death in schizophrenia in Stockholm county, Sweden

21 January 2018

1 reference

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

21 January 2018

1 reference

Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects

21 January 2018

1 reference

Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome

21 January 2018

1 reference

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

21 January 2018

1 reference

Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications

21 January 2018

1 reference

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

21 January 2018

1 reference

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

21 January 2018

1 reference

Metabolic syndrome with the atypical antipsychotics

21 January 2018

1 reference

Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents

21 January 2018

1 reference

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study

21 January 2018

1 reference

Abnormalities in glucose regulation associated with mental illness and treatment

21 January 2018

1 reference

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

The metabolic syndrome and schizophrenia

21 January 2018

1 reference

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review

21 January 2018

1 reference

Atypical antipsychotic drugs and the risk of sudden cardiac death

21 January 2018

1 reference

UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).

21 January 2018

1 reference

Atypical antipsychotic drugs and the risk of sudden cardiac death

21 January 2018

1 reference

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

21 January 2018

1 reference

Sudden death in patients receiving drugs tending to prolong the QT interval

21 January 2018

1 reference

Cardiac side effects of psychiatric drugs

21 January 2018

1 reference

Fatal cardiac event following initiation of risperidone therapy

21 January 2018

1 reference

May the best friend be an enemy if not recognized early: possible role of omega-3 against cardiovascular abnormalities due to antipsychotics in the treatment of autism

21 January 2018

1 reference

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?

21 January 2018

1 reference

Cardiomyopathy associated with clozapine

21 January 2018

1 reference

Adverse effects of atypical antipsychotics : differential risk and clinical implications

21 January 2018

1 reference

Apparent seizure and atrial fibrillation associated with paliperidone

21 January 2018

1 reference

Clozapine-induced myocarditis: role of catecholamines in a murine model

21 January 2018

1 reference

Cardiovascular magnetic resonance in mild to moderate clozapine-induced myocarditis: is there a role in the absence of electrocardiographic and echocardiographic abnormalities?

21 January 2018

1 reference

Late potentials in the signal-averaged electrocardiogram in schizophrenia patients maintained on antipsychotic agents: a preliminary naturalistic study.

21 January 2018

1 reference

Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.

21 January 2018

1 reference

A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients

21 January 2018

1 reference

Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study

21 January 2018

1 reference

An economic review of compliance with medication therapy in the treatment of schizophrenia

21 January 2018

1 reference

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

21 January 2018

1 reference

A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia

21 January 2018

1 reference

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

21 January 2018

1 reference

Risperidone versus haloperidol: II. Cost-effectiveness

21 January 2018

1 reference

Clinical trial-based cost-effectiveness analyses of antipsychotic use.

21 January 2018

1 reference

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

21 January 2018

1 reference

The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population

21 January 2018

1 reference

Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review

21 January 2018

1 reference

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial

21 January 2018

1 reference

Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model

21 January 2018

1 reference

Schizophrenia, "just the facts" 4. Clinical features and conceptualization

21 January 2018

1 reference

Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future

21 January 2018

1 reference

Adjunctive psychosocial therapies for the treatment of schizophrenia

21 January 2018

1 reference

Actions of ORG 5222 as a novel psychotropic agent

21 January 2018

1 reference

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

21 January 2018

1 reference

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

21 January 2018

1 reference

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

21 January 2018

1 reference

Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation

21 January 2018

1 reference

Evaluation of the clinical efficacy of asenapine in schizophrenia

21 January 2018

1 reference

Antipsychotic medication adherence: is there a difference between typical and atypical agents?

21 January 2018

1 reference

Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications.

21 January 2018

1 reference

The stable patient with schizophrenia--from antipsychotic effectiveness to adherence

21 January 2018

1 reference

Partial dopamine agonists in the treatment of psychosis

21 January 2018

1 reference

Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996.

21 January 2018

1 reference

Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain

21 January 2018

1 reference

Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.

21 January 2018

1 reference

National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

21 January 2018

1 reference

Impact of atypical antipsychotics on quality of life in patients with schizophrenia

21 January 2018

1 reference

Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study

21 January 2018

1 reference

Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.

21 January 2018

1 reference

Toward a new prevention of suicide in schizophrenia

21 January 2018

1 reference

Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison

21 January 2018

1 reference

Antipsychotics and risk of first-time hospitalization for myocardial infarction: a population-based case?control study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.11.82

1 reference

25 August 2017

1 reference